Is there need for intravascular ultrasound after high-pressure dilatations of Palmaz-Schatz stents  by Allen, Kathleen M. et al.
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Table 1 
Evenl 
Death 
Q.AMI 
non-Q AMI 
CABG 
rePTCA 
SAT 
In-hospital 
Total Ranking 
O 0 
0 0 
4 (2.5%) 4 
0 0 
1 (0.6%) 0 
1 (0.6%) o 
Discharge-- t mertth 
Total Ranking 
0 0 
1 (0.6%) 1 
0 0 
1 (0,6%) 1 
2 (1,3%) 2 
0 0 
slant thrombosis (SAT) and ~rdiac events were assessed in 160 pts, All pts 
received a single Palmaz-Sthatz sfont because of stable angina and u de 
nero coronary lesion. The protoCOl outlines that pts meeting the IVUS criteria 
of optimal stent expansion only receive ASA > 100 rag, while those not 
meeting the criteria receive ASA, oral and iv ant+coagulation after alenting. 
83% of the pts received ASA (of whom 17% should have been treated with 
anticoagulants ~ protocol violation) and 17=/= received systemio ant+coagu- 
lation. A total count of events and ranking according to the worst category 
analysis is shown in Table 1, 
This muiticentri¢ study confirms that stents can indeed be safely implanted 
without he institution of systemic anticoegulation. 
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~ - ~  Integrelin for Coronary Artery Stenting Emergency 
James P, Zidar, Kevin R. Kruse, Mark C. Thel, Dean Kereiakas, Joseph 
B, Muhlestsin, Chades J. Davidson, Paul S, Teirstein, Alan Tenaglia, Steven 
J. Yakubov, Jeffrey J. Popma, Jean-Francois Tanguay, Michael M. Kilt, Todd 
J. Lorenz, James E. Tcheng, A, Michael Lincoif, Robert M. Calliif, Eric 
J. Topoi for the IMPACT II Investigators. Duke University, Ourham, NC 
TO assess the potential benefit of GP lib/Ilia inhlbitors with COrOnary slant- 
ing, we studied 160 patients who required alents for true/threatened closure 
in the IMPACT it trial. In this trial of 4010 patients, no stents were placed 
eleclivaly by protocol design. A composite end point of death, MI, urgent 
repeat intervention or CABG was compared between the slant patients in 
the placebo arm vs. ptS randomized to one of two Integrelin doses. Baseline 
cheracleristi~ were similar betweer~ tho stent and n0n.stented groups. En- 
rollment status was characterized as high risk in 45% of patients in the stent 
group vs 41% in the non-slant group. Most (87%) slant patients received a 
Cook stent and were discharged on warfarin. 
Endpoints at 30 days! Integrefln (  = 101 ) Placebo (n = 59) p 
composite ndpeint 31% 49%. 0,021 
MI 16% 32% 0.017 
Urgent CABG ?% 8%,* 0,723 
Urgsnt repeal intervention G% 8% 0.546 
Death 2% 1.7% 0.897 
Major bleeding complication 21% 21% 0.956 
Conclusions: The high event rates in both groups reflect the "true bailout" 
indication for stsnting, Integrelin improves 30 day clinical outcome by reduc- 
ing the risk of MI in patients requiring slants after failed PTCA, without an 
increase in bleeding. This suggests the importance of GP lib/Ilia inhibition in 
coronary slanting. 
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~ l s  Them Need for Intravsscular Ultrasound After 
High-Pressure Dilatations of  Palmaz-Schatz Stente 
Kathioen M. Allen, Caned Undemlr. Alexander 8haknovich. Jeffrey Moses. 
Janet StE!n, Edward Kreps. Lsnox Hill Hospital, New York, NY 
Use of intrevescular ullre, sound (IVU,~) in conjunction with angiegraphio as- 
sessment of Palmaz-Schalz slants (PSSs) provided the rationale for routine 
post.deployment high pressure dilatation (HPD) of P,,~Ss. To address the 
question of whether outine NPD obviates the need for IVUS, we reviewed 
IVUS and quarditatlve angi0graphic (QCA) data in 91 pts with 96 lesions. 
HPO was performed in all pts (mean i:r(essure 16.7 4-1.6 ATM; range 14,-20 
ATM) with 1-1.1 balloon; artery ratio, Further imprevements were neces- 
ss~ In 4,5/96 vessels after post-HPD IVUS secondary to suboptimal stent 
geometry (32), I~Otn~ing tissue (5), and dissection/eddifional sten0sas (8). 
8 vessels requira~, additional PSSs and 37 further HPDs (17 with ~ same 
JACC Febm.~ry 1996 
and 2G with a ;arger balloon). IVUS (rt = 45) ~r~J ~A (n =* 30) wo~ repasted 
after each HPD. 
Pest HPD Final p value 
QGA MLO (ram) 2.66 ± 0.54 2.92 :E 0.50 0,055 
QCA stenoais % 5.95 ,.I- 8,86 -1.82,9.98 0,0007 
IVU8 MLD (ram) 2.81:1:0A1 3.10 + 0.39 0,001 
IVUS stenosis % 19.6 ± 9.2 9.85 :h 12,2 0,0002 
CSA (mm2) 7.5 ± 1.SS 8.97 + 2.03 0,001 
.Symmetry , 0.aS + 0.07 0.gO :~ 0.062 0,21 
Conclusions: In nearly half of P,~,Ss, IVUS folfowing HPD identified sub- 
optimal results which were improved with further intervention, A prospective 
randomized trial will be necessary to verify if this strategy alters clinical 
outcome. 
8:45 
~ Inlluence of  Size on the Late Restenotic Vessel 
Process After Successful  Stent Implantation 
Naeya Hamasaki, Hldeyuki Nasaka, Takeshi Kimure, Himyoshi Yok0i, 
Takashi Tamura, Yashihiro Sawada. Masakiyo Nobuysshi. Kitakyushu, 
Kokura Memorial Hospital, Japan 
The purpose of the present study was to investigate the influence of vessel 
size on late angiogrephic outcome after successful single stent placement, 
The study population compdsed 547 consecutive lesions implanted native 
artedes [Palmatz*$ohalz 436, Gianturco-Roubin 50, Cottlis. 61] and satis- 
factodc angiogrephic analysis before and after slanting and at 3 or 6 months 
follow-up (FUP) from a single center (Feb. 1990-Feb. 1995). 
Vassal size < 3.0 mm 3,0,-3.5 mrn > 3,5 mm 
Acute gain 1.86 + 0.67 2,05 + 0.44 2.22 :~ 0,55 P - 0.0001 
Late loss  0.89+0.67 0.97:1:0.64 0,81 :~0,65 P,= 0,56 
MLD FLIP 1.76±0,63 2.02:b 0,6 2,40~0.63 P ,~ 0,0001 
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Vessel size was found to be exert a significant positive influence on MLD 
at FUP and an equally negative elfect on loss by muifivadable analysis (p < 
0.001). The relative gain/loss relationships within the lesion groups showed 
that it does not vary with vessel size, In conclusion, vessel size ifse~11 does not 
influence the restenosls process, which appears to be determined mainly by 
the degree of luminal increase achieved at slanting, regardless of the veSsel 
size. 
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~ Dlatrlbutlon of  Tissue Growth In Palmaz-Schatz 
Stents: Ina l~t ts  F rom a Serial Intravascular 
Ultrasoun¢l'~fudy 
Ralner Hoffman, Gary S. Mlntz, Jeffrey J. Popma, Augusto D. Pichard, 
Lowell R Seller, Kenneth M. Kent, Roxana Mehreo, Martin B. Leon. 
Washington HospitaI Center, Washington, DC 
Previous studies have suggested that Instant restenosis is (1) due to inttmal 
hypelplasia and (2) occurs most frequently at the central articulation (CA) of 
Palmaz-Schatz slants. To understa~ this process, we compared Sedal {post- 
intervention and follow-up (F/U 5.4 4- 3.8 rues)} Intravasculm ultrasound 
studies in 104 slants implanted into 49 native and 39 SVG lesions, Lumerl 
and slant areas (in mm z) were measured; plaque (slant-lumen) area, late 
lumen toss (&lumen area) and tissue growth (&plaque area) were calculated 
for the edges, body, and CA of all slants: 
Edges., Body CA p(ANOVA) 
Post sterd area 10.t +4.1 9.5 • 3.6 9.6 :E 4.0 0.0005 
RU slant area 9.9+1:4.1 9.8 ~3.8 9,4+9.8 0.01 
Post lumen area  10.0+4.0 9.5±3.6 9.1:t:3.9 <0.000t 
F/U lumen area 7.1 :E3.9 8.5:1:3.6 6.0+4.1 <0.CO0t 
Post plaque area 0.0 + 0.1 0.0.4- 0.0 0.5 + 1.1 <0.0001 
F/U ¢A~ue ares 2.8:1:2.0 3.0 :I: 2.0 3,4 + 2.6 <0.0001 
Late lumen lo=~ 2.8:1:1.6 3.0:1:2.0 3,1 +25 NS 
T~s~gmwth 2.6 + 1.9 2.9 ± 2.0 2,8 + 2.5 NS 
The kntten 8t the cat,rat artJctdatton Is smaJler than at the bady or ¢:~v~ e! 
the rant besause of a s,g~y sma,er stem a~ea nd s ~  Wokmse 
